Tekla Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Tekla Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-265,045	Closed	-$7.54M	–	181
2018 Q1	$7.54M	Hold	265,045	–	–	0.29%	76
2017 Q4	$5.59M	Sell	265,045 -265,047	-50%	-$5.5M	0.22%	82
2017 Q3	$9.63M	Hold	530,092	–	–	0.34%	53
2017 Q2	$8.22M	Hold	530,092	–	–	0.3%	64
2017 Q1	$9.15M	Sell	530,092 -225,998	-30%	-$2.97M	0.36%	63
2016 Q4	$8.31M	Hold	756,090	–	–	0.35%	63
2016 Q3	$11.9M	Hold	756,090	–	–	0.46%	50
2016 Q2	$7.72M	Buy	756,090 +428,031	+130%	+$4.88M	0.32%	69
2016 Q1	$4.23M	Hold	328,059	–	–	0.18%	94
2015 Q4	$6.85M	Buy	+328,059	New	+$5.19M	0.25%	76

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Tekla Capital Management's CTMX Position: Q2 2018 in Review

Tekla Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2018, closing a stake of 265,045 shares — an estimated $7.54M sold.

Tekla Capital Management first reported a position in CTMX in Q4 2015 and held it in 10 quarters. The position peaked at $11.9M in Q3 2016. 142 funds tracked by Wall St. Rank hold CTMX as of Q2 2018.

Tekla Capital Management reported no remaining CytomX Therapeutics position as of Q2 2018 after selling out during the quarter.
Tekla Capital Management sold 265,045 CytomX Therapeutics shares in Q2 2018, an estimated $7.54M.
Tekla Capital Management first reported a position in CytomX Therapeutics in Q4 2015 and held it in 10 quarters.
Tekla Capital Management's CytomX Therapeutics position peaked at $11.9M in Q3 2016.
142 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2018.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.